flow trial semaglutide all-cause mortality hazard ratio Effectiveness of on survival outcomes in patients with type 2 diabetes and chronic kidney disease flow trial semaglutide all-cause mortality

Case studies illustrating the real-world impact of pharmacogenomics

In data presented at ObesityWeek 2022, adults with type 2 diabetes randomly assigned to at least 1.2 mg per week of BI 456906 (Boehringer Ingelheim) had greater reductions in HbA1c, weight loss and waist circumference compared with adults receiving semaglutide (Wegovy, Novo Nordisk), and the benefits for those receiving BI 456906 were greater for those taking a higher dose

Haran et al 2 underscore that the observed improvements in inflammatory skin disease, particularly psoriasis, often coincide with systemic metabolic changes, which confound direct attribution to immune effects

Meet Our Team Group Of Board Certified Providers A World-Class Group Of Board Certified Providers Dedicated to You